Impact of a Designated Hepatology Nurse on the Clinical Course and Quality of Life of Patients Treated With Rebetron™ Therapy for Chronic Hepatitis C

Gastroenterology Nursing

Volumn 27, Issue 4, 2004, Pages 149-155

  Ahern, Mary ^a   Imperial, Joanne ^a   Lam, Suzanna ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; REBETRON; RIBAVIRIN;

ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; FEMALE; GASTROENTEROLOGY; HEPATITIS C; HUMAN; MALE; NURSE ATTITUDE; NURSE PRACTITIONER; NURSING; OUTCOME ASSESSMENT; PHYSICIAN ATTITUDE; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; QUESTIONNAIRE; SICKNESS IMPACT PROFILE;

ANTIVIRAL AGENTS; DRUG COMBINATIONS; FEMALE; GASTROENTEROLOGY; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; NURSE PRACTITIONERS; NURSE'S ROLE; OUTCOME ASSESSMENT (HEALTH CARE); PHYSICIAN'S ROLE; QUALITY OF LIFE; QUESTIONNAIRES; RIBAVIRIN; SICKNESS IMPACT PROFILE;

EID: 7444271382     PISSN: 1042895X     EISSN: 15389766     Source Type: Journal    
DOI: 10.1097/00001610-200407000-00002     Document Type: Article

References (14)

1. Blair, C. S., Haydon, G. H., Cossar, J. A., Ewing, F. E. M., Miller R., O’Carroll, R.E., et al. (1997). Does chronic HCV infection affect quality of life?Gut, 41 (4S), 127A.
2. Bonkovsky, H. L., & Woolley, J. M. (1999). Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology, 29 (1), 264-270.
3. Davis, G. L., Balart, L. A., Schiff, E. R., Lindsay, K., Bodenheimer, H. C. Jr., et al. (1994). Assessing health-related quality of life in chronic hepatitis C using the Sickness Impact Profile. Clinical Therapeutics, 16 (2), 334-343.
4. Foster, G. R. (1999). Hepatitis C virus infection: Quality of life and side effects of treatment. Hepatology, 31 (S.1), 250-254.
5. Heitkemper, M., Jarrett, M., Kurashige, E., & Carithers, R. (2001). Chronic hepatitis C: Implications for health-related quality of life. Gastroenterology Nursing, 24 (4), 169-175.
6. McHutchison, J. G. (2002) Hepatitis C advances in antiviral therapy: What is accepted treatment now?Journal of Gastroenterology and Hepatology, 17 (4) 431-441.
7. McHutchison, J.G., Gordon, S. C., Schiff, E. R., Schiffman, M. L., Lee, W. M., Rustgi, V. K., et al. (1998). Interferon alfa 2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic hepatitis C. New England Journal of Medicine, 339 (21), 1485-1492.
8. McHutchison, J.G., Ware, J. E., Bayliss, M. S., Pianko, S., Albrecht, J. K., Cort, S., et al. (2001). The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. Hepatology, 34 (1), 140-147.
9. Perrillo, R., Rothstein, K. D., Rubin, R., Alam, I., Imperial, J., Harb, G., et al. (2004) Comparison of quality of life, work productivity and medical resource utilization of PEG interferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C. Journal of Viral Hepatitis, 11 (2), 157-165.
10. Poynard, T. Marcellin, P., Lee, S., Niederau, C., Minuk, G., Ideo, et al. (1998). Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet, 352 (9138), 1426-1432.
11. Rodger, A. J., Jolley, D., Thompson, S. C., Lanigan, A., & Crofts, N. (1999). The impact of diagnosis of hepatitis C virus on quality of life. Hepatology, 30 (5), 1299-1301.
12. Seeff, L. (1995). Natural history of viral hepatitis, type C. Seminars in Gastrointestinal Disease, 6 (1), 20-27.
13. Ware, J. E., Snow, K. K., Kosinski, M., & Gandek, B. (2000). The SF-36 health survey manual and interpretation guide. Lincoln, RI: Quality Metric Incorporated.
14. Wong, J. B., McQuillan, G. M., McHutchison, J. G., & Poynard, T. (2000). Estimating future hepatitis C morbidity, mortality, and sosts in the United States. American Journal of Public Health, 90 (10), 1562-1569.